- English
- Svenska

Financial reports

Read about our business activities and financial performance.

Home / Investors / Financial Reports

2021 Reports

Q1 EN

Interim Report Q2

Interim report Q3 21

Q1 EN oskarp

Annual report cover photo oskarp

Interim Report Q1

Interim report Q1 webcast

Interim Report Q2

Interim report Q2 webcast

Interim Report Q3

Interim report Q3 webcast

Year End Report 2021
To be released 2022-02-23

Annual Report 2021
TBA

2020 Reports

Q1 2020

Interim Report Q1

q2 2020

Interim Report Q2

2020-12-08_093831

Interim Report Q3

Year-End Report 2020

Year-End Report 2020

Year-End Report 2020 Webcast (Swedish)

Årsredovisning 2020 EN

Annual Report 2020

2019 Reports

q1 2019

Interim Report Q1

q2 2019

Interim Report Q2

2019 q3

Interim Report Q3

2019 YE report

Year End Report 2019

annual rep 2019

Annual Report 2019

2018 Reports

q2 2018

Interim Report Q2

2018 q3

Interim Report Q3

2018 YER

Year End Report 2018

annual report 2018

Annual Report 2018

2017 Annual Report (Swedish Language only)

2016 Annual Report (Swedish Language only)

Investor Communications

Latest news

Developers of Selektope®

I-Tech AB is a public held bio-technology company based in Mölndal, Sweden that owns all IP and regulatory rights to the antifouling agent Selektope® (generic name, medetomidine). I-Tech also controls the largest and most efficient source of medetomidine production.
Visit selektope.com

Contact information

info@i-tech.se
+46 10 30 33 999

I-Tech AB
c/o Astra Zeneca AB
Pepparedsleden 1
SE-431 83 Mölndal
Sweden